Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2013

Open Access 01-12-2013 | Research

Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis

Authors: Jun Cai, Hong Ma, Fang Huang, Dichao Zhu, Jianping Bi, Yang Ke, Tao Zhang

Published in: World Journal of Surgical Oncology | Issue 1/2013

Login to get access

Abstract

Background

With the wide application of targeted drug therapies, the relevance of prognostic and predictive markers in patient selection has become increasingly important. Bevacizumab is commonly used in combination with chemotherapy in the treatment of metastatic colorectal cancer. However, there are currently no predictive or prognostic biomarkers for bevacizumab. Several clinical studies have evaluated bevacizumab-induced hypertension in patients with metastatic colorectal cancer. This meta-analysis was performed to better determine the association of bevacizumab-induced hypertension with outcome in patients with metastatic colorectal cancer, and to assess whether bevacizumab-induced hypertension can be used as a prognostic factor in these patients.

Methods

We performed a systematic review and meta-analysis on seven published studies to investigate the relationship between hypertension and outcome of patients with metastatic colorectal cancer treated with bevacizumab. Our primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS) and overall response rate (ORR). Hazard ratios (HRs) for PFS and OS were extracted from each trial, and the log of the relative risk ratio (RR) was estimated for ORR.

Results

The occurrence of bevacizumab-induced hypertension in patients was highly associated with improvements in PFS (HR = 0.57, 95% CI: 0.46–0.72; P <0.001), OS (HR = 0.50; 95% CI: 0.37–0.68; P <0.001), and ORR (RR = 1.57, 95% CI: 1.07–2.30, P <0.05), as compared to patients without hypertension.

Conclusions

Bevacizumab-induced hypertension may represent a prognostic factor in patients with metastatic colorectal cancer.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.CrossRefPubMed
2.
3.
Tillmanns TD, Lowe MP, Walker MS, Stepanski EJ, Schwartzberg LS: Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecol Oncol. 2013, 128: 221-228. 10.1016/j.ygyno.2012.08.039.CrossRefPubMed
4.
Lombardi G, Zustovich F, Farina P, Fiduccia P, Della Puppa A, Polo V, Bertorelle R, Gardiman MP, Banzato A, Ciccarino P, Denaro L, Zagonel V: Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature. Anticancer Drugs. 2013, 24 (1): 90-97. 10.1097/CAD.0b013e32835aa5fd.CrossRefPubMed
5.
Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C, Central European Cooperative Oncology Group: Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol. 2013, 14: 125-133. 10.1016/S1470-2045(12)70566-1.CrossRefPubMed
6.
Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J, Durand JP, Treluyer JM, Knebelmann B, Goldwasser F: An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist. 2011, 16: 1325-1332. 10.1634/theoncologist.2010-0002.PubMedCentralCrossRefPubMed
7.
Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ: Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008, 26: 3743-3748. 10.1200/JCO.2007.15.5416.CrossRefPubMed
8.
Hasenohrl N: Bevacizumab in the first-line therapy of advanced NSCLC. Wien Med Wochenschr. 2007, 157: 576-578. 10.1007/s10354-007-0491-x. Article in GermanCrossRefPubMed
9.
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB, Eastern Cooperative Oncology Group Study E3200: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007, 25: 1539-1544. 10.1200/JCO.2006.09.6305.CrossRefPubMed
10.
Billemont B, Meric JB, Izzedine H, Taillade L, Sultan-Amar V, Rixe O: Angiogenesis and renal cell carcinoma. Bull Cancer. 2007, 94: S232-240. Article in FrenchPubMed
11.
Schuster C, Eikesdal HP, Puntervoll H, Geisler J, Geisler S, Heinrich D, Molven A, Lønning PE, Akslen LA, Straume O: Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS One. 2012, 7: e38364-10.1371/journal.pone.0038364.PubMedCentralCrossRefPubMed
12.
Galfrascoli E, Piva S, Cinquini M, Rossi A, La Verde N, Bramati A, Moretti A, Manazza A, Damia G, Torri V, Muserra G, Farina G, Garassino MC, ORION Collaborative Group: Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis. 2011, 43: 286-294. 10.1016/j.dld.2010.10.010.CrossRefPubMed
13.
Fuchs CS, Marshall J, Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008, 26: 689-690. 10.1200/JCO.2007.15.5390.CrossRefPubMed
14.
Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr Y, Saif MW, Schwartzberg L, Hedrick E: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol. 2008, 26: 3523-3529. 10.1200/JCO.2007.15.4138.CrossRefPubMed
15.
Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D, First BEAT investigators: Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2008, 20: 1842-1847.CrossRef
16.
Tahover E, Uziely B, Salah A, Temper M, Peretz T, Hubert A: Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol. 2013, 30: 327-CrossRefPubMed
17.
Osterlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, Bono P: Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer. 2011, 104: 599-604. 10.1038/bjc.2011.2.PubMedCentralCrossRefPubMed
18.
Horinouchi Y, Sakurada T, Nakamura T, Tajima S, Nishisako H, Abe S, Teraoka K, Kujime T, Kawazoe K, Minakuchi K: Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer. Yakugaku Zasshi. 2011, 131: 1251-1257. 10.1248/yakushi.131.1251. Article in JapaneseCrossRefPubMed
19.
De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S: Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol. 2011, 68: 1207-1213. 10.1007/s00280-011-1604-1.CrossRefPubMed
20.
Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S: Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2011, 20: 227-230.CrossRef
21.
Ryanne Wu R, Lindenberg PA, Slack R, Noone AM, Marshall JL, He AR: Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer. 2009, 40: 101-108. 10.1007/s12029-009-9104-9.CrossRefPubMed
22.
Dewdney A, Cunningham D, Barbachano Y, Chau I: Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. Br J Cancer. 2011, 106: 1718-1721.CrossRef
23.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000, 92: 205-216. 10.1093/jnci/92.3.205.CrossRefPubMed
24.
Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003, 13: 176-181. 10.1016/S1053-4296(03)00031-6.CrossRefPubMed
25.
Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998, 17: 2815-2834. 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8.CrossRefPubMed
26.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007, 2: 16-CrossRef
27.
28.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7: 177-188. 10.1016/0197-2456(86)90046-2.CrossRefPubMed
29.
Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994, 50: 1088-1101. 10.2307/2533446.CrossRefPubMed
30.
Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315: 629-634. 10.1136/bmj.315.7109.629.PubMedCentralCrossRefPubMed
31.
Kabbinavar F, Hurwitz HI, Fehrenbacher L: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003, 21: 60-65. 10.1200/JCO.2003.10.066.CrossRefPubMed
32.
Hurwitz H, Fehrenbacher L, Novotny W, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004, 350: 2335-2342. 10.1056/NEJMoa032691.CrossRefPubMed
33.
Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008, 359: 1757-1765. 10.1056/NEJMoa0804385.CrossRefPubMed
34.
Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD, ECOG 2100: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008, 26: 4672-4678. 10.1200/JCO.2008.16.1612.PubMedCentralCrossRefPubMed
Metadata
Title
Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis
Authors
Jun Cai
Hong Ma
Fang Huang
Dichao Zhu
Jianping Bi
Yang Ke
Tao Zhang
Publication date
01-12-2013
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2013
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-11-306

Other articles of this Issue 1/2013

World Journal of Surgical Oncology 1/2013 Go to the issue

Review

Characteristic analysis of α-fetoprotein-producing gastric carcinoma in China

Case report

Hypoglossal nerve monitoring, a potential application of intraoperative nerve monitoring in head and neck surgery

Research

S100A7 enhances invasion of human breast cancer MDA-MB-468 cells through activation of nuclear factor-κB signaling

Case report

Primary malignant melanoma of the esophagus: a rare and aggressive disease

Case report

About a submucosal tracheal tumor

Case report

Partial response after transcatheter arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable colon cancer and hepatic metastasis: (case report)